Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease

In an effort to combat Alzheimer's disease, Acumen Pharmaceuticals Inc. (NASDAQ: ABOS) will be hosting a conference call today to discuss the positive results from the Phase 1 INTERCEPT-AD trial of ACU193, a clinical-stage antibody therapy for early Alzheimer's disease. The conference call will feature Acumen's leadership team, as well as renowned experts in the field such as Steven DeKosky, M.D..